Sweden· SE-20250228000069
Rybrevant 2240 mg Injektionsvätska, lösning
A medicinal product containing amivantamab, registered in Sweden by Janssen-Cilag International NV.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Amivantamab
- Manufacturer
- Janssen-Cilag International NV
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20250228000069
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Amivantamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRybrevant 2240 mgJanssen-Cilag International
- CzechiaRYBREVANTJanssen-Cilag International N.V., Beerse
- SpainRYBREVANT 2240 MG SOLUCION INYECTABLEJanssen-Cilag International N.V
- NorwayRybrevantJanssen-Cilag International N.V.
- PolandRybrevantJanssen-Cilag International N.V.
- NetherlandsRybrevant 1600 mg, oplossing voor injectieJanssen-Cilag International NV
- FinlandRybrevantJanssen Cilag International
- IcelandRybrevantJanssen-Cilag International NV*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rybrevant
- Liechtenstein · Rybrevant
- Norway · Rybrevant
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c751109f-9a29-4cab-9dd5-fec7ae7c7f65 GET /v1/drugs/c751109f-9a29-4cab-9dd5-fec7ae7c7f65?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EMA",
"EPAR"
],
"se_npl_id": "20250228000069",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20250228000069",
"product_doc_link": "https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant"
}See everything about amivantamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.